Cognetivity Neurosciences (CGN) signs agreement, leading to commercial deployment at leading psychiatry and neurology centre in UAE The platform is used in medical, commercial and consumer environments The center is also an accredited research body, having worked with Harvard Medical School Center for Global Health Delivery In the future, the deployment may be expanded to cover additional ACPN services CognICA™ is approved for clinical use in the USA and EU, with approval already in the UAE Cognetivity Neurosciences (CGN) is unchanged on the day, trading at C$ 0.32 per share
Cognetivity Neurosciences (CGN) has signed a commercial agreement with American Center for Psychiatry and Neurology (ACPN).
Cognetivity Neurosciences is a tri-listed company that has created a unique brain health screening platform. The platform is used in medical, commercial and consumer environments.
ACPN is a specialist medical facility with branches in the cities of Abu Dhabi, Dubai and Al Ain.
The facility works to provide high-quality neurological, psychiatric, psychological and rehabilitation services and is a leading provider of its kind in the UAE.
The center is also an accredited research body, having been involved in numerous high-profile published studies in the region. Not to mention, it has ongoing research collaborations with the Harvard Medical School Center for Global Health Delivery, Biogen, Novartis and IQVIA.
The commercial agreement will use Cognetivity’s CognICA brain health screening platform as a screening and monitoring tool at ACPN’s newly established memory clinic.
In the future, the deployment may be expanded to cover additional ACPN services, supporting studies in the Alzheimer’s disease space and more.
CognICA is approved for clinical use in the USA and EU, with approval already in the UAE, North America and in the UK’s National Health Service (NHS).
The technology uses AI and machine learning techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function.
Aiding in CognICA to detect early health issues in individuals with brain health problems.
Professor Tadros to oversee the agreement
The new deployment will be overseen by Professor George Tadros, a consultant geriatric psychiatrist at ACPN and Vice-Chair of the center’s Institutional Review Board.
Professor Tadros is excited about the new work that is to be done. “At ACPN, we are committed to providing the highest-quality […] care.”
“CognICA has all the credentials necessary to drive this at our new memory clinic – I look forward greatly to seeing its positive impact on our patients,” added Professor Tadros.
Dr. Sina Habibi, CEO of Cognetivity, went on to add that the team is looking forward to the deal. “CognICA is the perfect tool in every way for this job, and this latest implementation further shows our technology’s value to progressive healthcare centers and systems.”
Cognetivity is a technology company that is in the business of helping people with cognitive issues.
Cognetivity Neurosciences (CGN) is unchanged on the day, trading at C$ 0.32 per share.
The post Cognetivity Neurosciences (CSE:CGN) signs agreement with leading psychiatry and neurology centre in UAE appeared first on The Market Herald Canada.
Cognetivity Neurosciences (CSE:CGN) signs agreement with leading psychiatry and neurology centre in UAE